AlphAIalphai — Financial news for AI agents
WKYCMAY 72 min read$HAE

Haemonetics: Fiscal Q4 Earnings Snapshot

Haemonetics Corp. (HAE) reported a loss of $20.1 million, or 44 cents per share, in its fiscal fourth quarter, though adjusted earnings of $1.29 per share surpassed analyst expectations. The company also exceeded revenue forecasts, posting $346.4 million for the quarter. For the full year, Haemonetics reported a profit of $97.3 million on revenue of $1.33 billion.

Original reporting
WKYC · Associated Press
Published May 7, 2026, 1:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 7, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Haemonetics: Fiscal Q4 Earnings Snapshot — source image
Source · WKYC
Decision brief

The 30-second read

$HAENeutralMed
01

Why it matters

The earnings report indicates resilience in adjusted earnings but highlights ongoing challenges with net losses, suggesting cautious optimism.

02

Market read

Limited broader market impact; primarily relevant to investors and analysts tracking healthcare sector earnings.

03

What to watch

Potential impact of upcoming product launches or regulatory changes not covered in the report could influence future performance.

Timing: Immediate, as earnings reports can cause short-term volatility.

Background

Haemonetics is a key player in the blood management and plasma collection industry, with recent investments in new technology platforms.

Company-level read

Ticker impact

$HAENeutralMedium confidence
Context

The company's quarterly earnings report shows mixed results with a net loss but better-than-expected adjusted earnings and revenue, indicating potential short-term trading opportunities.

Expected impact

Potential short-term upward movement due to beat on adjusted earnings and revenue, despite net loss.

Evidence & confidence

The positive surprise in adjusted earnings and revenue may boost investor confidence temporarily, but the net loss indicates underlying challenges. Technical analysis and broader market conditions should be monitored for confirmation.

Market effects

Sector

The life sciences sector may experience slight positive sentiment, but overall impact is limited due to mixed earnings signals.

Regional

Minimal regional impact; primarily affects investors focused on US-based healthcare companies.

Global

Low; the news is company-specific without broader global implications.

Counterpoint

What could challenge this read

The net loss suggests underlying operational issues; the stock may decline in the near term despite the positive earnings surprise.

Key entities

  • Company
    Haemonetics Corp.

    A global healthcare company specializing in blood management solutions.

Read at source← All news

Related articles

AUG 9
$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.

yahoo.com6 min
AUG 6
$HAEMed

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Haemonetics (NYSE:HAE) reported Q2 CY2026 results. Revenue rose 5.6% year on year to $339.4 million, exceeding Wall Street estimates by 2.8%. Non-GAAP adjusted EPS was $1.14, up from $1.10 and 5.8% above consensus. Analysts expect revenue growth of about 5% over the next 12 months and full-year EPS to rise from $5.01 to $5.36.

financialcontent.com6 min
AUG 6
$HAEHigh

HAEMONETICS CORP (HAE): Results of Operations and Financial Condition

HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-fy27q1earningsrelease.htm EX-99.1 Document Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.git

SEC EDGAR 8-K4 min
AUG 9
$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

dailysabah.com6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min